COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,889 Articles (22,568 medRxiv, 8,321 bioRxiv)

Most recent first Previous |  Page 853: Articles 8521-8530  | Next

Social connections at work and mental health during the first wave of the COVID-19 pandemic: Evidence from employees in Germany
Breetzke, J., Wild, E.-M.
10.1101/2022.03.04.22270966 — Posted: 2022-03-07
A rapid review of the effectiveness of alternative education delivery strategies in medical, dental, nursing and pharmacy education during the COVID-19 pandemic
Carrier, J., Edwards, D., Tombs, M., Lewis, R., Gillen, E., Riley, S., Cooper, A., Edwards, A.
10.1101/2022.03.04.22271892 — Posted: 2022-03-07
A systematic review about skin lesions in children affected by Coronavirus Disease 2019 (excluding multisystem inflammatory syndrome in children): study protocol.
Dondi, A., Sperti, G., Gori, D., Montalti, M., Parini, L., Guaraldi, F., Lanari, M., Neri, I.
10.1101/2022.03.04.22271888 — Posted: 2022-03-07
Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
Chalkias, S., Schwartz, H., Nestorova, B., Feng, J., Chang, Y., Zhou, H., Dutko, F. J., Edwards, D. K., Montefiori, D., Pajon, R., Leav, B., Miller, J. M., Das, R.
10.1101/2022.03.04.22271830 — Posted: 2022-03-07
SARS-CoV-2 triggers Golgi fragmentation via downregulation of GRASP55 to facilitate viral trafficking
Zhang, J., Kennedy, A., Xing, L., Bui, S., Reid, W., Joppich, J., Ahat, E., Rose, M., Tang, Q., Tai, A. W., Wang, Y.
10.1101/2022.03.04.483074 — Posted: 2022-03-07
Predicted binding interface between coronavirus nsp3 and nsp4
Hensel, Z.
10.1101/2022.03.05.483145 — Posted: 2022-03-07
Intragenomic rearrangements of SARS-CoV-2 and other β-coronaviruses
Patarca, R., Haseltine, W. A.
10.1101/2022.03.07.483258 — Posted: 2022-03-07
mRNA-based vaccine candidate COReNAPCIN(R) induces robust humoral and cellular immunity in mice and non-human primates
Alimohammadi, R., Porgoo, M., Eftekhary, M., Kiaie, S. H., Ansari Dezfouli, E., Dehghani, M., Nasrollah, K., Malekshahab, T., Heidari, M., Pouya, S., Alimohammadi, M., Sattari Khavas, D., Modaresi, M. S., Ghasemi, M. H., Ramyar, H., Mohammadipour, F., Hamzelouei, F., Mofayezi, A., Mottaghi, S. S., Rahmati, A., Razzaznian, M., Tirandazi, V., Borzouee, F., Sadeghi, H., Haji Mohammadi, M., Rastegar, L., Safar Sajadi, S. M., Ehsanbakhsh, H., Bazmbar, H., Shams Nouraee, M., Pazooki, P., Pahlevan Neshan, M., Alishah, K., Nasiri, F., Mokhberian, N., Mohammadi, S. S., Akar, S., Niknam, H., Azizi, M., Ajoudanian, M., Moteallehi-Ardakani, M. H., Mousavi Shaegh, S. A., Ramezani, R., Salimi, V., Moazzami, R., Hashemi, S. M., Dehghanizadeh, S., Khoddami, V.
10.1101/2022.03.05.483092 — Posted: 2022-03-07
Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease
Zhou, P., Song, G., He, W.-t., Beutler, N., Tse, L. V., Martinez, D. R., Schafer, A., Anzanello, F., Yong, P., Peng, L., Dueker, K., Musharrafieh, R., Callaghan, S., Capozzola, T., Yuan, M., Liu, H., Limbo, O., Parren, M., Garcia, E., Rawlings, S. A., Smith, D. M., Nemazee, D., Jardine, J. G., Wilson, I. A., Safonova, Y., Rogers, T., Baric, R. S., Gralinski, L. E., Burton, D. R., Andrabi, R.
10.1101/2022.03.04.479488 — Posted: 2022-03-07
Potent universal-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody
Piepenbrink, M. S., Park, J.-G., Deshpande, A., Loos, A., Ye, C., Basu, M., Sarkar, S., Chauvin, D., Woo, J., Lovalenti, P., Erdmann, N. B., Goepfert, P. A., Truong, V. L., Bowen, R. A., Walter, M. R., Martinez-Sobrido, L., Kobie, J. J.
10.1101/2022.03.05.483133 — Posted: 2022-03-07

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).